contact us
sort news by author
Emma Petela, GK Strategy, Jamie Cater, Louise Allen, Robin Grainger,
sort news by category
Insight, Strategy, Impact,
apprenticeships, awards, B2G, Biden, Bills, Blueprint, bolt on, Boris, Boris Johnson, Brexit, business, careers, climate change, clinical trials, commissioning, Communications, Consumer, consumer demands, covid, COVID 19, Crisis comms, culture, d, David Laws, defence, Deregulation, Devolution, Digital, Disruption, diversity, Due Diligence, economic policy, Education, Energy, Energy and Environment, engagement, Environment, Equality, ESG, EU, europe, exit plan, Financial Services, general election, General News, gig economy, GK culture, gk report, Government, government affairs, Health, health and social care, health funding, health insights, Healthcare, Hendy, housing, HS2, i have a voice, infrastructure, insight, insight report, insights, integrated review, internship, Investment, Investor, Investor Backed Businesses, Investor Services, investors, Ioan, Jack Sansum, Jeremy Corbyn, labour conference, Labour market, Legislation, life sciences, local government, lockdown, medical devices, Medicines, membership bodies, mental health, mental health services, nationalisation, NHS, no, No deal, parliament, pharma, pharmaceuticals, Planning, policy, Political Due Diligence, Politics, Pride Month, Prime Minister, Private Equity, Privatisation, Public Affairs, Public Relations, Public spending, Queen's Speech, rail, recruitment, REF, regulation, sales, Scott, Select Committee, select committees, skills, Social Care, Spending Review, Strategic Communications, students, sustainability, Tax, Technology, The Conservative Party, The Labour Party, trade bodies, transformation, Transport, uk, UK Politics, university, US, US election, Waste, Winter Plan, women, Workplace,
David Laws, GK adviser, former MP and Cabinet Minister shares his thoughts on the next steps for Brexit.
Brexit: Where next?
Only a year ago, British politics was dominated by the debate about Brexit. It says a lot for the impact of COVID-19 that since early March the virus and its huge economic, health and social impacts have relegated Brexit news to a few paragraphs on the inside pages of one or two Brexit-focused newspapers. But Brexit has in no sense gone away. The end of the transition period on 31st December 2020 looms ever closer, and Boris Johnson has made clear that in spite of COVID, he is not willing to...
COVID-19: Short and long term policy impacts for investors and companies
The policy impacts of COVID-19 will not just extend to the many measures designed to help the economy over the next few months. The political and regulatory world will change profoundly and for the long term. We are advising investors, portfolio companies and other organisations on what help is available and how they can best advocate for and access assistance. The Government has shown its willingness to engage with business and respond to requests for greater clarity, revised eligibility...
How the Conservative majority will change political risk for investors
The Conservatives’ majority of 80 seats has removed one of the biggest political risks to investors. A hung parliament, let alone a Labour administration, will remain a distant possibility. The Prime Minister no longer needs to tread carefully to win votes in the Commons. Yet, the actions of this single-party government – the first significant majority in the UK for over a decade – will be more complex to forecast. The dynamics of Parliament and politics have changed...
Brexit , Deregulation , Disruption , Due Diligence , Education , Government , government affairs , insight , Labour market , NHS , policy , Politics , Privatisation , Public spending , Tax , UK Politics
Can Labour’s manifesto trigger “real change” in the polls?
Since parliament voted for a December 12 election, Labour has made some progress in the polls – with the party now polling at 29% (it stood at 24% immediately before the election was called). However, Corbyn still finds his party trailing Boris Johnson’s by around a dozen points. The party’s hopes now rest on it’s radical manifesto, but will this be enough to close the gap? A manifesto of “hope”? Corbyn has so far struggled to cut through in the election...
Brexit , general election , Government , nationalisation , NHS , policy , Politics , The Labour Party
3 min read3 misconceptions about the 2019 general election
Although the contest to enter Number 10 is in its infancy, there are already a number of dominant narratives beginning to take shape – and perhaps mistakenly so. 'Boris Johnson is heading for a majority' Despite Jeremy Corbyn stating that Labour have been ready for an election ever since the last, the party has long given the impression it is running scared of an...
Boris Johnson , Brexit , general election , Government , Jeremy Corbyn , Politics , Prime Minister , The Conservative Party , The Labour Party , UK Politics
2 min readWeak pound and economic uncertainty: an opportunity for US investors?
With uncertainty over Brexit continuing to hit investor confidence and the “Pound on a rollercoaster” in the currency markets, there has been a noticeable slowdown in deal volume in the domestic M&A market whilst people wait for a resolution...
Brexit makes understanding devolution in England more important than ever
Most discourse on Brexit and the future of the UK looks at how it could impact Scotland, Wales, and Northern Ireland. England is often overlooked in such analyses. Yet the UK's departure from the EU will have significant fiscal, policy, and political impacts for the largest, most populous UK nation. Devolution in England has been sporadic, to say the least. A total of 12 deals were agreed between government and regional authorities between 2014 and 2017 – but no further agreements have...
Brexit , Devolution , Government , local government , UK Politics
Europe and the supply of innovative medicines: why it matters
One of the standout features of the ‘no-deal’ Brexit debate has been the focus on the impact on supplies of medicines and medicinal products. This includes everything from chemical compounds and investigational medicinal products (IMPs) for clinical research through to short shelf-life medicines made on the continent. The debate has been a continuous battle between those outlining the possible impact on patients’ lives while struggling to quantify the extent of the impact. Some areas...